skip to the content

Clinical Trials

Crohn's Disease - Pediatric Study

A Phase 2, open-label, multicenter study to assess the safety and efficacy of certolizumab pegol in children and adolescents with active Crohn’s disease (NURTURE Study)

Protocol ID

09-10-87

Protocol Description

Certolizumab pegol is a medication that has been approved for treatment of adults with Crohn's disease. The purpose of this study is to evaluate the effectiveness and safety of certolizumab pegol in chldren with Crohn's disease.

Eligibility Criteria

Children with Crohn's disease

Primary Investigator(s)

  • James Markowitz, MD

Contact Information

Kathleen Grancher
(718) 470-3363
kgranche@nshs.edu

Last Update

March 30, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Children's Health:
top
top